{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:27:48Z","timestamp":1793755668429,"version":"4.6.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":272,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.lrr.2026.100614","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:40:41Z","timestamp":1790836841000},"page":"100614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prolonged, transplant-free remission with tagraxofusp in combination with venetoclax for transplant-ineligible blastic plasmacytoid dendritic cell neoplasm"],"prefix":"10.1016","volume":"26","author":[{"given":"Tia","family":"Cheunkarndee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2444-0862","authenticated-orcid":false,"given":"Claire","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8202-0870","authenticated-orcid":false,"given":"Gabriel","family":"Mannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lrr.2026.100614_bib0001","doi-asserted-by":"crossref","DOI":"10.1182\/hem.V22.5.202551","article-title":"Blastic plasmacytoid dendritic cell neoplasm: clinical recognition and importance of a rare hematologic malignancy","volume":"22","author":"Pemmaraju","year":"2025","journal-title":"Hematologist"},{"issue":"2","key":"10.1016\/j.lrr.2026.100614_bib0002","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.2012.072645","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.lrr.2026.100614_bib0003","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood.2022017865","article-title":"North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need","volume":"141","author":"Pemmaraju","year":"2023","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.lrr.2026.100614_bib0004","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1002\/cncr.35315","article-title":"Tagraxofusp, a first-in-class CD123-targeted agent: five-year postapproval comprehensive review of the literature","volume":"130","author":"Jen","year":"2024","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.lrr.2026.100614_bib0005","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3390\/cancers11091358","article-title":"CD123 as a therapeutic target in the treatment of hematological malignancies","volume":"11","author":"Testa","year":"2019","journal-title":"Cancers. (Basel)"},{"issue":"26","key":"10.1016\/j.lrr.2026.100614_bib0006","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.22.00034","article-title":"Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm","volume":"40","author":"Pemmaraju","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lrr.2026.100614_bib0007","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3324\/haematol.2022.282171","article-title":"Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm","volume":"109","author":"Luskin","year":"2024","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.lrr.2026.100614_bib0008","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.lrr.2026.100614_bib0009","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1200\/JCO-25-02083","article-title":"Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm","volume":"44","author":"Pemmaraju","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lrr.2026.100614_bib0010","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1172\/JCI128571","article-title":"DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance","volume":"129","author":"Togami","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.lrr.2026.100614_bib0011","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","article-title":"Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax","volume":"7","author":"Montero","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lrr.2026.100614_bib0012","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/s41375-026-03022-0","article-title":"Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II","volume":"40","author":"Beird","year":"2026","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.lrr.2026.100614_bib0013","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1007\/s00277-020-04276-z","article-title":"Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm","volume":"99","author":"Schwede","year":"2020","journal-title":"Ann. Hematol."},{"issue":"100380","key":"10.1016\/j.lrr.2026.100614_bib0014","article-title":"Venetoclax monotherapy as front-line therapy for blastic plasmacytoid dendritic cell neoplasm","volume":"20","author":"Shah","year":"2023","journal-title":"Leuk. Res. Rep."},{"issue":"2","key":"10.1016\/j.lrr.2026.100614_bib0015","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1002\/ajh.26417","article-title":"Venetoclax and hypomethylating agents in older\/unfit patients with blastic plasmacytoid dendritic cell neoplasm","volume":"97","author":"Gangat","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lrr.2026.100614_bib0016","article-title":"Venetoclax combined with azacitidine in blastic plasmacytoid dendritic cell neoplasm: a case report and comprehensive review on the current and future treatment","volume":"11","author":"Wang","year":"2024","journal-title":"Front. Med. (Lausanne)"},{"issue":"9","key":"10.1016\/j.lrr.2026.100614_bib0017","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1080\/10428194.2025.2498046","article-title":"A case series of oral decitabine-cedazuridine with venetoclax for blastic plasmacytoid dendritic cell neoplasm","volume":"66","author":"Goulart","year":"2025","journal-title":"Leuk. Lymphoma"},{"issue":"Supplement 1","key":"10.1016\/j.lrr.2026.100614_bib0018","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1182\/blood-2025-4612","article-title":"Longer survival with tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): results of a real-world analysis","volume":"146","author":"Stein","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.lrr.2026.100614_bib0019","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1182\/blood-2025-653","article-title":"Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): results of a phase 2 trial","volume":"146","author":"Lane","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2026.100614_bib0020","unstructured":"Study details. Accessed 10 May 2026. https:\/\/clinicaltrials.gov\/study\/NCT03113643."},{"key":"10.1016\/j.lrr.2026.100614_bib0021","unstructured":"Study details. Accessed 10 May 2026. https:\/\/clinicaltrials.gov\/study\/NCT04216524."},{"issue":"16_suppl","key":"10.1016\/j.lrr.2026.100614_bib0022","doi-asserted-by":"crossref","first-page":"6502","DOI":"10.1200\/JCO.2026.44.16_suppl.6502","article-title":"A phase II trial of tagraxofusp, hyper-CVAD, and venetoclax for patients with newly diagnosed or relapsed\/refractory BPDCN","volume":"44","author":"Goulart","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lrr.2026.100614_bib0023","unstructured":"Efficacy and Safety of Pivekimab Sunirine (PVEK) in Patients (pts) With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in the CADENZA Study. - ASCO. Accessed 10 May 2026. https:\/\/www.asco.org\/abstracts-presentations\/244202."},{"issue":"19","key":"10.1016\/j.lrr.2026.100614_bib0024","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/bloodadvances.2020002474","article-title":"Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients","volume":"4","author":"Laribi","year":"2020","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.lrr.2026.100614_bib0025","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.2019001144","article-title":"Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark","volume":"134","author":"Taylor","year":"2019","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.lrr.2026.100614_bib0026","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/bloodadvances.2020001875","article-title":"Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant","volume":"4","author":"Yun","year":"2020","journal-title":"Blood Adv."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048926000543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048926000543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:10:41Z","timestamp":1793754641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048926000543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":26,"alternative-id":["S2213048926000543"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2026.100614","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolonged, transplant-free remission with tagraxofusp in combination with venetoclax for transplant-ineligible blastic plasmacytoid dendritic cell neoplasm","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2026.100614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100614"}}